Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 26.7M 24.83M 22.59M 42.65M 2.89B 42.83M 299M 117M 1.47B 112M 110M 4.73B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.74M 9.99M 9.09M 17.16M 1.16B 17.23M 120M 47.11M 593M 45.15M 44.17M 1.9B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
09-14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
09-11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
09-08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
09-01 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
08-24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
08-05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
08-05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
07-16 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT
07-16 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer CI
1 day+1.28%
1 week-1.73%
Current month-7.24%
1 month+9.37%
3 months+9.07%
6 months-12.56%
Current year-44.16%
1 week 3.87
Extreme 3.87
4.22
1 month 3.48
Extreme 3.48
4.43
Current year 2.6
Extreme 2.6
12.1
1 year 2.6
Extreme 2.6
14.68
3 years 2.6
Extreme 2.6
895.5
5 years 2.6
Extreme 2.6
1,870.5
10 years 2.6
Extreme 2.6
8,100.08
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%-1.73% - - 33.97M
-2.59%-5.70%+40.86%+83.11% 72.13B
+3.23%-10.67%+4.87%+55.97% 49.41B
+1.56%+1.17%+5.15%+33.38% 47.24B
+1.58%-7.57%+301.13%+649.90% 40.32B
+1.12%+1.38%+28.95%+31.19% 42.61B
+1.56%-0.67%+5.92%+105.84% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+5.18%-0.21%-7.45%-11.54% 23.13B
+3.78%+8.33%+18.40%+0.33% 21.09B
Average +1.44%-3.91%+45.04%+110.94% 40.7B
Weighted average by Cap. +0.94%-4.28%+47.74%+118.39%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.28M -3.98M -3.62M -6.84M -464M -6.87M -47.91M -18.77M -236M -17.99M -17.6M -759M -26.31M -23.5M -21.86M -19.88M -37.54M -2.55B -37.7M -263M -103M -1.3B -98.81M -96.65M -4.17B
Net Debt -862K -770K -716K -651K -1.23M -83.43M -1.24M -8.62M -3.38M -42.54M -3.24M -3.17M -137M -17.87M -15.96M -14.84M -13.5M -25.49M -1.73B -25.6M -179M -70M -882M -67.09M -65.62M -2.83B
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-10-09 US$3.970 +1.28% 18,878
26-10-08 US$3.920 -2.00% 48,704
26-10-07 US$4.000 -0.50% 84,514
26-10-06 US$4.020 -3.83% 69,125
26-10-05 US$4.180 +3.47% 59,548

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.